Scale-down to Scale-up
Successful scale-up to manufacture new bio-based products can be accelerated by rigorous and innovative approaches to scale down the relevant processes during development. Development of manufacturing technology transfer packages requires trial-and-error to optimize myriad factors, in cell line development, fermentation process development, and downstream processing development. This session will discuss how an expanded ability to screen through many combinations quickly, cheaply, and predictively increases the scope and profitability of industrial biotechnology.
Diversification in Products
The scope and reach of applications and products within industrial biotechnology continues to expand at a rapid clip, as the business and sustainability needs for manufacturing innovations continues to increase and the enabling technologies continue to develop (ranging from powerful genome editing to breakthrough automation miniaturization to advanced computation and data sciences). Relatively new applications include novel vaccine ingredients, animal-free meat and dairy, flavor and aroma ingredients for diverse products, fungal apparel and packaging materials, and novel functional ingredients from plant secondary metabolism—some of which will be discussed in this session.
Consumer, Government, and Regulatory Perspectives for Rapid Innovation
Developing a scalable, cost effective industrial biotech process is just the first step in achieving commercial viability - the target product must also earn consumer acceptance, government support, and regulatory approval. As we continue to expand and diversify the types of products industrial biotech can deliver, this session will help foster successful understanding and management of consumer, government, and regulatory perspectives, which is imperative for realizing the full potential of this industry.
Nimble Development: how to fail fast, reduce time & cost, and increase probability of success
The historically high costs and long timelines for development of requisite technology to manufacture novel bio-based products has prevented wider adoption of this approach to manufacturing. As the industry matures and implements 21st Century technological breakthroughs, this session will share some lessons learned and emerging best practices that can increase and accelerate success with lower development costs.
Circular Economy: valuing sustainability and a green premium
The circular green economy is becoming a key component of industrial biotechnology’s value proposition and markets, as diverse stakeholders ranging from the Biden administration and other governments to multinational corporations focus increasingly on long-term sustainability, renewable carbon, and reducing environmental impact. This session will discuss sustainability metrics, the "green" premium, and the valorization of waste streams.
Eye on the Prize: building an integrated process and supply chain
For successful commercialization of new bio-based products, it is critical to (re)evaluate the market pull, business case, and technoeconomic model at the outset and throughout the development. An integrated approach from living cells to chemical processes to steel factory is necessary, with interdependent co-optimization. This session will share approaches and case studies illustrating how to integrate design and development of the living and chemical catalysts, fermentation and recovery processes, and manufacturing equipment.